Spyre Therapeutics (SYRE) Preferred Shares (2015 - 2026)

Spyre Therapeutics (SYRE) has 4 years of Preferred Shares data on file, last reported at $9.4 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Shares changed N/A year-over-year to $9.4 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (changed N/A YoY), and the FY2025 full-year result was $146.4 million, up 1458.54% from the prior year.
• Preferred Shares for Q1 2026 stood at $9.4 million, down from $146.4 million in the prior quarter.
• Across five years, Preferred Shares topped out at $184.9 million in Q1 2024 and bottomed at $9.4 million in Q4 2024.
• The 3-year median for Preferred Shares is $146.4 million (2024), against an average of $107.2 million.
• Peak annual rise in Preferred Shares reached 1458.54% in 2025, while the deepest fall reached 1458.54% in 2025.
• A 3-year view of Preferred Shares shows it stood at $9.4 million in 2024, then surged by 1458.54% to $146.4 million in 2025, then slumped by 93.58% to $9.4 million in 2026.
• The last three Preferred Shares figures came in at $9.4 million (Q1 2026), $146.4 million (Q4 2025), and $9.4 million (Q4 2024), per Business Quant data.

Peer Comparison